seen from China
seen from Indonesia
seen from United States
seen from Netherlands
seen from Malaysia
seen from China
seen from Hungary
seen from Portugal
seen from Germany
seen from China
seen from Pakistan
seen from Yemen
seen from United States
seen from United Kingdom
seen from Australia
seen from Yemen
seen from Indonesia
seen from United States
seen from Singapore
seen from Singapore
Cancer treatment: Two studies presented at the ESMO 2019 indicated that many new anti-cancer medicines added little clinical benefit for patients.
Advances in cancer treatments, such as immunotherapies and precision medicines, have been associated with a corresponding rise in the cost of new and innovative medicines.
Pharmaceutical companies are focusing on the development of combination treatments for heavily pre-treated and refractory patient populations.
Despite advances in the renal cell carcinoma (RCC) therapy landscape, the majority of patients with RCC will eventually develop resistance to available therapies and the disease will progress through several stages, requiring further lines of treatment.
Novartis has announced results from the Monaleesa-3 trial at the European Society for Medical Oncology (ESMO) Congress 2019.
Novartis has said that Kisqali delivered superior overall survival (OS) in the Monaleesa-3 trial, demonstrating more life for postmenopausal human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer patients.
At ESMO 2019, Samsung Bioepis reveals positive results from Phase 3 study comparing its SB8 with Avastin in patients with metastatic or recurrent NSCLC.
A Phase 3 study comparing Samsung Bioepis’ SB8 with Avastin in patients with metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC) demonstrated equivalent efficacy in terms of risk ratio of overall response rate (ORR).
Pharmaceutical Technology lists seven promising digital health intervention companies participating in the ESMO Congress 2019 conference.
Digital health interventions (DHIs) are fast emerging as vital tools to promote personal health and provide essential services. DHIs can be accessed through mobile phones, tablets and computers, as well as serve as effective support systems to improve personal health.
Medical Device Network lists seven promising liquid biopsy companies participating in the ESMO Congress 2019 conference being held in September.
Liquid biopsy, a minimally invasive cancer diagnostic tool, has gained momentum in the last five years due to its advantages over the archaic painful procedure of solid tumour biopsy.
